TCT 2024: ALIGN-AR 2-year Outcomes from the ALIGN-AR Trial

Presented as Late-Breaking Science from TCT 2024, Dr. Torsten Vahl presents a 2 year update to the pivotal ALIGN-AR Trial, studying the safety and efficacy of the TAVR with the dedicated Trilogy valve for patients with moderate-to-severe and severe aortic regurgitation that are at high-risk for surgery.